CONTEXT: Subclinical hypothyroidism (SCH) has been associated with an increased risk for cardiovascular disease. However, few studies have specifically examined the association between SCH and myocardial infarction (MI), and the relationship is poorly understood. OBJECTIVES: The purpose of this study was to evaluate incident MI risk in relation to SCH and severities of SCH among postmenopausal women. METHODS: We used a population-based nested case-cohort design within the Women's Health Initiative observational study to examine the association between SCH and incident first-time MI risk among postmenopausal women in the United States. SCH was assessed using blood specimens collected at baseline. Participants presenting with normal free T4 levels and with thyrotropin levels of greater than 4.68-6.99 mU/L or 7.00 mU/L or greater were defined as having mild SCH or moderate/severe SCH, respectively. MI cases were centrally adjudicated by trained Women's Health Initiative staff. The primary analysis included 736 incident MI cases and 2927 randomly selected subcohort members. Multivariable adjusted Cox-proportional hazard models were used to assess MI risk in relation to SCH. RESULTS: Compared with euthyroid participants, the multivariable adjusted hazard ratio (HR) for participants with any SCH was 1.05 [95% confidence interval (CI) 0.77-1.44]. HRs for participants with mild SCH, moderate/severe SCH, and moderate/severe SCH and the presence of antithyroid peroxidase antibodies (TPOAb) were 0.99 (95% CI 0.67-1.46), 1.19 (95% CI 0.72-1.96), and 0.90 (95% CI 0.47-1.74), respectively. CONCLUSION: We did not find evidence to suggest that SCH is associated with increased MI risk among a population of predominantly older postmenopausal women with no prior history of MI.
CONTEXT: Subclinical hypothyroidism (SCH) has been associated with an increased risk for cardiovascular disease. However, few studies have specifically examined the association between SCH and myocardial infarction (MI), and the relationship is poorly understood. OBJECTIVES: The purpose of this study was to evaluate incident MI risk in relation to SCH and severities of SCH among postmenopausal women. METHODS: We used a population-based nested case-cohort design within the Women's Health Initiative observational study to examine the association between SCH and incident first-time MI risk among postmenopausal women in the United States. SCH was assessed using blood specimens collected at baseline. Participants presenting with normal free T4 levels and with thyrotropin levels of greater than 4.68-6.99 mU/L or 7.00 mU/L or greater were defined as having mild SCH or moderate/severe SCH, respectively. MI cases were centrally adjudicated by trained Women's Health Initiative staff. The primary analysis included 736 incident MI cases and 2927 randomly selected subcohort members. Multivariable adjusted Cox-proportional hazard models were used to assess MI risk in relation to SCH. RESULTS: Compared with euthyroid participants, the multivariable adjusted hazard ratio (HR) for participants with any SCH was 1.05 [95% confidence interval (CI) 0.77-1.44]. HRs for participants with mild SCH, moderate/severe SCH, and moderate/severe SCH and the presence of antithyroid peroxidase antibodies (TPOAb) were 0.99 (95% CI 0.67-1.46), 1.19 (95% CI 0.72-1.96), and 0.90 (95% CI 0.47-1.74), respectively. CONCLUSION: We did not find evidence to suggest that SCH is associated with increased MI risk among a population of predominantly older postmenopausal women with no prior history of MI.
Authors: B M Psaty; T D Koepsell; T A Manolio; W T Longstreth; E H Wagner; P W Wahl; R A Kronmal Journal: J Clin Epidemiol Date: 1990 Impact factor: 6.437
Authors: John P Walsh; Alexandra P Bremner; Max K Bulsara; Peter O'Leary; Peter J Leedman; Peter Feddema; Valdo Michelangeli Journal: Arch Intern Med Date: 2005-11-28
Authors: Anne R Cappola; Linda P Fried; Alice M Arnold; Mark D Danese; Lewis H Kuller; Gregory L Burke; Russell P Tracy; Paul W Ladenson Journal: JAMA Date: 2006-03-01 Impact factor: 56.272
Authors: Nicolas Rodondi; Anne B Newman; Eric Vittinghoff; Nathalie de Rekeneire; Suzanne Satterfield; Tamara B Harris; Douglas C Bauer Journal: Arch Intern Med Date: 2005-11-28
Authors: M P Vanderpump; W M Tunbridge; J M French; D Appleton; D Bates; F Clark; J Grimley Evans; D M Hasan; H Rodgers; F Tunbridge Journal: Clin Endocrinol (Oxf) Date: 1995-07 Impact factor: 3.478
Authors: M P Vanderpump; W M Tunbridge; J M French; D Appleton; D Bates; F Clark; J Grimley Evans; H Rodgers; F Tunbridge; E T Young Journal: Thyroid Date: 1996-06 Impact factor: 6.568
Authors: Giorgio Iervasi; Sabrina Molinaro; Patrizia Landi; Maria Chiara Taddei; Elena Galli; Fabio Mariani; Antonio L'Abbate; Alessandro Pingitore Journal: Arch Intern Med Date: 2007-07-23
Authors: Jennifer S Mammen; John McGready; Rachael Oxman; Chee W Chia; Paul W Ladenson; Eleanor M Simonsick Journal: Thyroid Date: 2015-08-13 Impact factor: 6.568
Authors: Tinh-Hai Collet; Douglas C Bauer; Anne R Cappola; Bjørn O Asvold; Stefan Weiler; Eric Vittinghoff; Jacobijn Gussekloo; Alexandra Bremner; Wendy P J den Elzen; Rui M B Maciel; Mark P J Vanderpump; Jacques Cornuz; Marcus Dörr; Henri Wallaschofski; Anne B Newman; José A Sgarbi; Salman Razvi; Henry Völzke; John P Walsh; Drahomir Aujesky; Nicolas Rodondi Journal: J Clin Endocrinol Metab Date: 2014-06-10 Impact factor: 5.958
Authors: Ayush Giri; Todd L Edwards; Vicky A LeGrys; Carol E Lorenz; Michele Jonsson Funk; Robin Schectman; Gerardo Heiss; Jennifer G Robinson; Katherine E Hartmann Journal: Thyroid Date: 2014-06-16 Impact factor: 6.568